Animas Insulin Infusion Pump Recall Issued Due to False Alarm, Warnings

|

A Class I recall has been issued for specific Animas insulin infusion pumps, due to a risk that a component in the pump may trigger a false alarm or warning, prompting the user to initiate a reset process that can be dangerous if not completed properly. 

An Animas 2020 Infusion Insulin Pump recall was initially issued on January 3, but it was re-announced on April 4, after the manufacturer noticed a component in the pump may trigger a warning related to “loss of prime”, “occlusion”, “no cartridge detected”.

The insulin infusion pump problems pose a potential hazard for users, as it will prompt the user to run a complete “rewind, load and prime” process and if the pump is not detached from the user during this reset, an unintended amount of insulin may be administered to the user, posing serious health risks and even death.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

Animas 2020 Infusion Insulin Pumps manufactured from March 1, 2012 to November 30, 2012 are impacted by the recall. The pumps are equipped with a software limitation that only allows the pump to run until December 31, 2015. After this date the device will display a “Call Service Alarm”.

The FDA has designated the action as a Class I recall, which suggests that continued use of the product poses a serious risk of severe adverse health consequences or death.

The manufacturer advises consumers with the recalled Animas insulin pumps to carefully follow the rewind, load and prime process by detaching the machine from their body when the pump alarms. Consumers should also contact Animas’ Product Fulfillment Center at (877) 280-2339 to schedule a free shipping of a replacement pump. Users are also encouraged to report any adverse events to FDA’s MedWatch Safety Information and Adverse Event Reporting Program by completing and submitting the report online at www.fda.gov/MedWatch/report.htm or call 1-800-332-1088 to request the reporting form.

Written by: Russell Maas

Managing Editor & Senior Legal Journalist

Russell Maas is a paralegal and the Managing Editor of AboutLawsuits.com, where he has reported on mass tort litigation, medical recalls, and consumer safety issues since 2010. He brings legal experience from one of the nation’s leading personal injury law firms and oversees the site’s editorial strategy, including SEO and content development.

Image Credit: |



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

In the first federal trial over claims of Uber driver sexual assaults, a lawsuit involving the rape of a passenger will go before a jury on January 13.
More than 2,000 Depo-Provera brain tumor lawsuits have been filed in state and federal courts nationwide, according to recent court documents, with potentially thousands more claims pending.
A federal judge will meet with lead counsel in the Suboxone litigation tomorrow to receive an update on the number of Suboxone lawsuits filed and the status of discovery.